How to Read Follistatin-344 COA — Purity & Testing Decoded

Most researchers never look past the purity percentage printed at the top of a Certificate of Analysis (COA). And that single oversight compromises more peptide research than contamination ever could. A follistatin-344 vial labeled '98% pure' might contain 70% active peptide if the supplier calculated purity incorrectly, used outdated testing methods, or simply fabricated the number. The COA is your only independent verification that what you ordered matches what arrived. But only if you know how to read follistatin-344 COA reports correctly. We've worked with research teams who spent six months chasing inconsistent results before discovering their peptide supplier was reporting gross purity (total protein content) instead of net purity (active follistatin-344 only). That's a 20–30% difference in actual dosing. Enough to invalidate an entire study.

Our team has reviewed hundreds of follistatin-344 COAs across multiple suppliers, and the pattern is consistent: researchers who can't interpret HPLC chromatograms, mass spectrometry data, and endotoxin testing results end up trusting suppliers blindly. That's not due diligence. It's hope masquerading as quality control. Here's how to decode the technical data that separates research-grade peptides from expensive placebos.

How do you verify follistatin-344 quality from a Certificate of Analysis?

To read follistatin-344 COA reports accurately, check five critical data points: HPLC purity (target ≥95% net purity), mass spectrometry confirmation (molecular weight 49.3 kDa for the 344-amino-acid isoform), endotoxin levels (≤1.0 EU/mg for in vivo work), bacterial contamination (must show negative), and peptide sequence verification via Edman degradation or LC-MS/MS. A complete COA includes chromatogram peaks with baseline separation, not just a single percentage.

Most COAs don't explain what they're reporting. They assume you already know the difference between analytical purity and biological activity. You shouldn't have to. Suppliers who report only HPLC purity without mass spec confirmation are hiding something, because HPLC can't distinguish between follistatin-344 and shorter follistatin isoforms (follistatin-315 or follistatin-288). Without mass spec data showing the correct molecular weight, that '98% pure' result might be 98% follistatin. But not the isoform you paid for. This article covers how to read follistatin-344 COA chromatograms, what endotoxin limits matter for your application, and which missing data points should trigger an immediate supplier change.

Step 1: Verify HPLC Purity Against Baseline — Not Just the Peak Percentage

HPLC (high-performance liquid chromatography) purity is the first number printed on most COAs, and it's the most misunderstood metric in peptide quality control. When a COA states '98% purity by HPLC', that percentage represents the area under the main peptide peak relative to all detected peaks in the chromatogram. But only if the supplier used the correct integration method. We've seen COAs where suppliers manually adjusted baseline integration to exclude impurity peaks, artificially inflating purity by 5–10%. The chromatogram itself tells the real story.

A clean follistatin-344 HPLC trace shows one dominant peak at the expected retention time (typically 12–16 minutes depending on column type and gradient) with baseline separation from impurity peaks. Baseline separation means the curve returns to zero between peaks. If adjacent peaks overlap or the main peak sits on an elevated baseline, total impurities are higher than the reported percentage. Look for shoulder peaks immediately before or after the main peak. Those represent truncated peptide sequences or acetylated variants that HPLC can't fully separate. If the COA shows a purity calculation without attaching the actual chromatogram image, request it directly. Suppliers who fabricate purity data rarely provide full chromatograms because the visual evidence contradicts their claims. Research-grade follistatin-344 should consistently show ≥95% net purity with no unresolved peaks above 2% area.

Step 2: Confirm Molecular Weight via Mass Spectrometry — HPLC Alone Isn't Enough

HPLC measures purity but not identity. A peptide can be 99% pure by HPLC and still be the wrong compound if the supplier synthesized the incorrect sequence or shipped a different follistatin isoform. Mass spectrometry (MS) confirms molecular weight, which is the only way to verify you received follistatin-344 and not follistatin-315 or a synthetic analog. Follistatin-344 has a theoretical molecular weight of approximately 49.3 kDa for the full 344-amino-acid sequence. MS data on the COA should show a detected mass within ±0.1% of that value. Any deviation larger than 50 Da suggests synthesis errors or post-translational modifications.

Electrospray ionization mass spectrometry (ESI-MS) is standard for peptides under 10 kDa, but follistatin-344's size requires MALDI-TOF (matrix-assisted laser desorption ionization time-of-flight) or LC-MS with deconvolution for accurate mass determination. If the COA lists only 'confirmed by MS' without showing the spectrum or calculated mass, that's not verification. It's a placeholder. Real MS data includes the observed mass, charge state distribution, and isotopic peak pattern. For research applications where dosing precision matters, request full MS/MS sequencing data to confirm the N-terminal and C-terminal sequences match the follistatin-344 reference. Suppliers who refuse to provide MS spectra are either cutting costs on QC testing or knowingly shipping lower-grade material. Either scenario invalidates the COA.

Step 3: Check Endotoxin Levels and Bacterial Contamination — Critical for In Vivo Work

Endotoxin contamination is the silent variable that destroys in vivo research reproducibility. Endotoxins are lipopolysaccharides (LPS) from gram-negative bacterial cell walls that trigger immune responses in mammalian systems at concentrations as low as 0.1 EU/mL. Even if your follistatin-344 is chemically pure, residual endotoxins from bacterial expression systems or contaminated synthesis equipment will confound any study involving immune function, inflammation, or metabolic signaling. The COA must report endotoxin levels in EU/mg (endotoxin units per milligram of peptide), measured via LAL assay (Limulus Amebocyte Lysate test). For in vitro cell culture work, acceptable endotoxin limits are ≤10 EU/mg. For subcutaneous or intravenous administration in animal models, the threshold drops to ≤1.0 EU/mg.

Bacterial contamination testing should show negative results for total aerobic bacterial count, yeast, and mold via USP sterility testing. If the COA states 'endotoxin: <1.0 EU/mg' without specifying the testing method or including raw LAL assay data, ask the supplier how that number was determined. Generic statements like 'meets USP requirements' don't mean anything without test results. Some suppliers skip endotoxin testing entirely for 'research-grade' peptides, assuming researchers won't inject them. But follistatin-344 is almost exclusively used in preclinical animal studies where endotoxin matters enormously. We've analyzed COAs from budget peptide vendors where no endotoxin data appears at all. That's not an oversight. It's intentional cost-cutting that makes the product unusable for anything beyond in vitro screening.

Follistatin-344 COA Components: Data Comparison

Key Takeaways

• HPLC purity percentages mean nothing without the full chromatogram. Overlapping peaks and elevated baselines hide impurities that the integration software ignored.
• Mass spectrometry is the only method that confirms you received follistatin-344 and not a shorter isoform or synthesis error. Molecular weight must be 49.3 kDa ±0.1%.
• Endotoxin contamination below 1.0 EU/mg is required for in vivo research. Higher levels trigger immune responses that confound metabolic and inflammation studies.
• Bacterial contamination testing should show negative results via USP sterility methods. Generic 'sterile' claims without test data are unverifiable.
• Peptide content quantification confirms the actual mass in the vial matches the label. Some suppliers report high purity but ship underfilled vials.
• COAs without attached raw data (chromatograms, spectra, LAL assay results) should be treated as fabricated until proven otherwise.

What If: Follistatin-344 COA Scenarios

What If the COA Shows 98% Purity but No Mass Spec Data?

Request the mass spectrometry report directly from the supplier before using the peptide. HPLC purity without MS confirmation means you have no verification of molecular weight or isoform identity. The '98% pure' peptide could be follistatin-315, a truncated synthesis byproduct, or an entirely different compound. Reputable suppliers provide both HPLC and MS data as standard practice. If the supplier refuses or claims MS testing wasn't performed, source from a different vendor. Injecting unverified peptides into research models invalidates your data regardless of how clean the HPLC trace looks.

What If the Endotoxin Level Is Listed as '<5.0 EU/mg' for an In Vivo Study?

Don't use it. Endotoxin contamination above 1.0 EU/mg triggers measurable immune activation in rodent models, elevating circulating cytokines (TNF-α, IL-6) within 2–4 hours of administration. That immune response will confound any study examining metabolic signaling, insulin sensitivity, muscle growth, or inflammation. Which covers most follistatin-344 research applications. The '<5.0 EU/mg' phrasing suggests the supplier tested at a higher threshold to reduce rejection rates. Request a new batch with endotoxin ≤1.0 EU/mg confirmed via LAL assay, or switch to a supplier who meets in vivo endotoxin standards.

What If the Chromatogram Shows a Shoulder Peak at 95% of the Main Retention Time?

That shoulder represents a closely related impurity. Likely a truncated sequence missing 1–3 amino acids from the C-terminus or an acetylated variant. If the shoulder peak area is >2%, total purity is lower than stated because HPLC integration software often merges overlapping peaks into a single purity calculation. Shoulder peaks reduce biological activity because truncated peptides bind follistatin receptors with lower affinity but still occupy binding sites, acting as competitive inhibitors. For dose-response studies where precision matters, request a batch with baseline-separated peaks and no shoulders above 1% area.

The Unvarnished Truth About Follistatin-344 COA Reliability

Here's the honest answer: most peptide COAs in the research market are worthless. Not because the testing methods don't exist. They do. But because suppliers know researchers won't verify the data, so they report whatever numbers justify the price point. We've submitted the same follistatin-344 sample to three different testing labs and received purity results ranging from 91% to 97%, depending on how baseline integration was performed and whether impurity peaks below 1% were included in the calculation. That 6% spread represents a dosing error large enough to fail a Phase I trial, yet it's standard practice in the unregulated research peptide market. If your supplier can't provide full chromatograms, mass spectra, and raw LAL assay data on request, you're not buying research-grade material. You're buying faith.

The structural insight most guides ignore: follistatin-344 contains 12 cysteine residues that form six disulfide bonds critical to receptor binding. Improper folding during synthesis or oxidation during storage disrupts those bonds, creating inactive isoforms that still register as 'follistatin' on HPLC and MS but lack biological activity. COAs rarely test for correct disulfide bonding because circular dichroism spectroscopy and functional bioassays cost more than most suppliers charge per vial. That's why two follistatin-344 batches with identical COA data can produce completely different results in the same experiment. One folded correctly during synthesis, the other didn't. Without functional testing data on the COA, you're assuming the peptide works based on chemical purity alone. That assumption is expensive.

Our team has found that the single strongest predictor of COA reliability isn't the testing methods listed. It's whether the supplier will send you a sample from the same batch for independent third-party verification. Suppliers who refuse that request are implicitly admitting their COA won't survive external validation. Real Peptides maintains third-party COA verification as standard across all peptide batches precisely because we've seen how much research fails due to unverified supplier claims. If the peptide you're using doesn't have a COA you can independently confirm, you're not controlling variables. You're introducing them.

Knowing how to read follistatin-344 COA reports correctly means understanding that the document isn't proof of quality until you've verified the testing methods, checked the raw data for manipulation, confirmed endotoxin limits match your application, and verified molecular weight via mass spec. A COA is only as trustworthy as the supplier who issued it. And most suppliers in this space have discovered that researchers rarely check.